Stock Breakout: Discussions on social media highlight AbCellera's recent technical breakout above key resistance levels, with volume supporting the move and targets eyed at $10.50 to $12.50. Observers note the stock's strong performance amid broader biotech interest in AI-driven platforms.
Pipeline Momentum: Recent posts emphasize the company's partnership with Jazz Pharmaceuticals for multispecific antibodies in cancer, alongside internal assets like ABCL635 advancing toward Phase II data in 2026. A robust balance sheet with hundreds of millions in liquidity is frequently cited as providing runway for execution.
Market Sentiment: Overall tone reflects optimism as the stock climbs, with many pointing to derisking events like lawsuit resolutions and insider activity as catalysts for further re-rating potential.
Note: This discussion summary was generated from an AI condensation of post data.
AbCellera Biologics Insider Trading Activity
AbCellera Biologics insiders have traded $ABCL stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ABCL stock by insiders over the last 6 months:
- HOLDINGS LTD. THERMOPYLAE has made 2 purchases buying 215,457 shares for an estimated $711,004 and 0 sales.
- ANDREW BOOTH (Chief Financial Officer) purchased 42,600 shares for an estimated $145,692
- JOHN S. MONTALBANO purchased 20,000 shares for an estimated $95,399
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
AbCellera Biologics Hedge Fund Activity
We have seen 72 institutional investors add shares of AbCellera Biologics stock to their portfolio, and 78 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAILLIE GIFFORD & CO removed 10,422,966 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $35,646,543
- TWO SIGMA INVESTMENTS, LP added 4,751,080 shares (+81.8%) to their portfolio in Q1 2026, for an estimated $16,581,269
- BAKER BROS. ADVISORS LP added 2,750,298 shares (+10.0%) to their portfolio in Q1 2026, for an estimated $9,598,540
- JEFFERIES FINANCIAL GROUP INC. added 2,746,200 shares (+inf%) to their portfolio in Q1 2026, for an estimated $9,584,238
- TANG CAPITAL MANAGEMENT LLC removed 2,600,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $8,892,000
- ALYESKA INVESTMENT GROUP, L.P. added 2,592,105 shares (+inf%) to their portfolio in Q1 2026, for an estimated $9,046,446
- UBS GROUP AG added 2,269,643 shares (+117.0%) to their portfolio in Q1 2026, for an estimated $7,921,054
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
AbCellera Biologics Price Targets
Multiple analysts have issued price targets for $ABCL recently. We have seen 2 analysts offer price targets for $ABCL in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Steve Seedhouse from Cantor Fitzgerald set a target price of $7.0 on 05/05/2026
- Debanjana Chatterjee from Jones Trading set a target price of $11.0 on 04/10/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
